Azuca, provider of fast-acting cannabis delivery systems, and BDSA, provider of market intelligence for the cannabis industry, have released the 2025 Edibles Premiumization Report.

Based on verified retail sales data from BDSA, the report finds that fast-acting gummies are reshaping the $2.57 billion U.S. gummy market, commanding premium pricing and outperforming traditional SKUs.

“This research validates what we’ve been seeing firsthand: premium in cannabis is defined by performance, not price,” said Corinne Butler, SVP of growth, Azuca. “We’re seeing fast-acting products earn top placement because they meet those expectations — and because consumers are willing to pay more for quality and consistency.”

Key findings from the report include:

• Premium Pricing: Customers are paying 31% higher original price and 39% higher sell-through price for fast-acting gummies compared to the average of all other gummy types (100 mg THC). Fast-acting SKUs are priced highest — and discounted the least — showing strong consumer willingness to pay.
• Per SKU Dominance: Despite being a smaller segment, fast-acting products generate four to five times more sales per SKU than non-mood-specific gummies, which are historically the category’s volume leader.
• Brand Performance: Brands with fast-acting products in their portfolio rank higher in BDSA’s national dollar sales rankings than those without; 50% of sales generated are from fast-acting products
• High-Velocity Retail Presence: Fast-acting edibles are preferentially stocked in high-volume dispensaries and are essential for competitive distribution.
• Category Lift, Not Cannibalization: Fast-acting edibles do not cannibalize traditional or mood-specific SKUs. Instead, they expand the category by attracting repeat buyers and increasing overall spend.
• Consumer Loyalty: On average, baskets with a fast-acting SKU are six times more likely to include another fast-acting unit, signaling repeat behavior.

“Fast-acting SKUs are overperforming across nearly every key metric we track — from pricing to velocity to brand rank,” said Katie Rizik, director of client solutions, BDSA. “Brands launching fast-acting gummies can expect significantly higher sales per product than with traditional 100 mg non-mood-specific SKUs, which face heavier competition and lower demand.”